Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.

@article{Marshall2005PhaseIS,
  title={Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.},
  author={John Marshall and James L. Gulley and Philip M. Arlen and Patricia K Beetham and K. Roger Tsang and Rebecca Slack and James W Hodge and Sandra Doren and Douglas W. Grosenbach and Jimmy H Hwang and Evelyn Fox and Lauretta Odogwu and Susie Park and Dennis L. Panicali and Jeffrey Schlom},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 4},
  pages={720-31}
}
PURPOSE Our previous clinical experience with vaccinia and replication-defective avipox recombinant carcinoembryonic antigen (CEA) vaccines has demonstrated safety and clinical activity with a correlation between CEA-specific immune response and survival. Preclinical evidence demonstrated that the addition of the transgenes for three T-cell costimulatory molecules (B7-1, ICAM-1, LFA-3, designated TRICOM) results in a significant improvement in antigen-specific T-cell responses and antitumor… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
80 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 80 extracted citations

Similar Papers

Loading similar papers…